Valerio Santarelli, Davide Rosati, V. Canale, S. Salciccia, G. Di Lascio, Giulio Bevilacqua, A. Tufano, Alessandro Sciarra, Vito Cantisani, Giorgio Franco, Martina Moriconi, Giovanni Battista Di Pierro
{"title":"对比增强超声 (CEUS) 目前在膀胱癌诊断和分期中的作用:现有文献综述","authors":"Valerio Santarelli, Davide Rosati, V. Canale, S. Salciccia, G. Di Lascio, Giulio Bevilacqua, A. Tufano, Alessandro Sciarra, Vito Cantisani, Giorgio Franco, Martina Moriconi, Giovanni Battista Di Pierro","doi":"10.3390/life14070857","DOIUrl":null,"url":null,"abstract":"Contrast-enhanced ultrasound (CEUS) is an advanced imaging technique that integrates conventional US with the intravenous injection of specific US contrast agents (UCAs), combining the non-invasiveness of US with the higher accuracy of contrast-enhanced imaging. In contrast with magnetic resonance imaging (MRI), computed tomography (CT) and cystoscopy, CEUS has few contraindications, and UCAs are non-nephrotoxic agents that can be safely used in patients with kidney failure. CEUS is a well-established method for the detection of liver lesions and for echocardiography, and its indications are expanding. The updated 2018 WFUMB-EFSUMB guidelines have added the urinary bladder under non-hepatic applications of CEUS. The technique is able to distinguish between benign tissue, such as clots or hematoma, and malignant lesions by perfusing the mass with contrast agent. Thanks to the different perfusion rates of the various layers of the bladder wall, CEUS is also able to predict tumor invasion depth and stage. Despite that, current urological guidelines do not include CEUS as a plausible imaging technique for bladder urothelial carcinoma. The main reason for this omission might be the presence of scarce randomized evidence and the absence of large validated series. In this review, we describe the rationale behind the use of CEUS in bladder cancer and the added value of this imaging technique in the detection and staging of bladder lesions. In addition, we researched the available literature on the topic and then described the results of randomized clinical trials and a meta-analysis investigating the accuracy of CEUS in bladder cancer diagnosis and staging. The reported studies show that CEUS is a highly accurate diagnostic and staging tool for BC, reaching levels of specificity and sensitivity in differentiating between Ta-T1, or low-grade BC, and T2, or high-grade BC, that are comparable to those shown by the reference standard methods. Nonetheless, several limitations were found and are highlighted in this review. The aim of this study is to further validate and promote the use of CEUS as a quick, economic and effective diagnostic tool for this high-impact disease.","PeriodicalId":18182,"journal":{"name":"Life","volume":"64 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Current Role of Contrast-Enhanced Ultrasound (CEUS) in the Diagnosis and Staging of Bladder Cancer: A Review of the Available Literature\",\"authors\":\"Valerio Santarelli, Davide Rosati, V. Canale, S. Salciccia, G. Di Lascio, Giulio Bevilacqua, A. Tufano, Alessandro Sciarra, Vito Cantisani, Giorgio Franco, Martina Moriconi, Giovanni Battista Di Pierro\",\"doi\":\"10.3390/life14070857\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Contrast-enhanced ultrasound (CEUS) is an advanced imaging technique that integrates conventional US with the intravenous injection of specific US contrast agents (UCAs), combining the non-invasiveness of US with the higher accuracy of contrast-enhanced imaging. In contrast with magnetic resonance imaging (MRI), computed tomography (CT) and cystoscopy, CEUS has few contraindications, and UCAs are non-nephrotoxic agents that can be safely used in patients with kidney failure. CEUS is a well-established method for the detection of liver lesions and for echocardiography, and its indications are expanding. The updated 2018 WFUMB-EFSUMB guidelines have added the urinary bladder under non-hepatic applications of CEUS. The technique is able to distinguish between benign tissue, such as clots or hematoma, and malignant lesions by perfusing the mass with contrast agent. Thanks to the different perfusion rates of the various layers of the bladder wall, CEUS is also able to predict tumor invasion depth and stage. Despite that, current urological guidelines do not include CEUS as a plausible imaging technique for bladder urothelial carcinoma. The main reason for this omission might be the presence of scarce randomized evidence and the absence of large validated series. In this review, we describe the rationale behind the use of CEUS in bladder cancer and the added value of this imaging technique in the detection and staging of bladder lesions. In addition, we researched the available literature on the topic and then described the results of randomized clinical trials and a meta-analysis investigating the accuracy of CEUS in bladder cancer diagnosis and staging. The reported studies show that CEUS is a highly accurate diagnostic and staging tool for BC, reaching levels of specificity and sensitivity in differentiating between Ta-T1, or low-grade BC, and T2, or high-grade BC, that are comparable to those shown by the reference standard methods. Nonetheless, several limitations were found and are highlighted in this review. The aim of this study is to further validate and promote the use of CEUS as a quick, economic and effective diagnostic tool for this high-impact disease.\",\"PeriodicalId\":18182,\"journal\":{\"name\":\"Life\",\"volume\":\"64 5\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Life\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/life14070857\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Life","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/life14070857","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
对比增强超声(CEUS)是一种先进的成像技术,它将传统 US 与静脉注射特定 US 造影剂(UCAs)结合在一起,既有 US 的无创性,又有对比增强成像的高准确性。与磁共振成像(MRI)、计算机断层扫描(CT)和膀胱镜检查相比,CEUS 几乎没有禁忌症,而且 UCAs 是无肾毒性的制剂,可安全地用于肾衰竭患者。CEUS 是一种检测肝脏病变和超声心动图的成熟方法,其适应症正在不断扩大。2018 年更新的 WFUMB-EFSUMB 指南在 CEUS 的非肝脏应用中增加了膀胱。该技术通过用造影剂灌注肿块,能够区分血块或血肿等良性组织和恶性病变。由于膀胱壁各层的灌注率不同,CEUS 还能预测肿瘤的侵犯深度和分期。尽管如此,目前的泌尿外科指南并未将 CEUS 作为膀胱尿路上皮癌的一种可行成像技术。造成这种遗漏的主要原因可能是缺乏随机证据和大型验证系列。在这篇综述中,我们阐述了在膀胱癌中使用 CEUS 的基本原理,以及这种成像技术在膀胱病变检测和分期中的附加价值。此外,我们还研究了现有的相关文献,然后介绍了随机临床试验和荟萃分析的结果,这些试验和分析调查了 CEUS 在膀胱癌诊断和分期中的准确性。所报告的研究表明,CEUS 是一种高度准确的膀胱癌诊断和分期工具,在区分 Ta-T1 或低级别膀胱癌和 T2 或高级别膀胱癌方面的特异性和灵敏度水平与参考标准方法相当。尽管如此,本综述还是发现了一些局限性。本研究的目的是进一步验证和推广 CEUS 的使用,将其作为一种快速、经济、有效的诊断工具来治疗这种影响较大的疾病。
The Current Role of Contrast-Enhanced Ultrasound (CEUS) in the Diagnosis and Staging of Bladder Cancer: A Review of the Available Literature
Contrast-enhanced ultrasound (CEUS) is an advanced imaging technique that integrates conventional US with the intravenous injection of specific US contrast agents (UCAs), combining the non-invasiveness of US with the higher accuracy of contrast-enhanced imaging. In contrast with magnetic resonance imaging (MRI), computed tomography (CT) and cystoscopy, CEUS has few contraindications, and UCAs are non-nephrotoxic agents that can be safely used in patients with kidney failure. CEUS is a well-established method for the detection of liver lesions and for echocardiography, and its indications are expanding. The updated 2018 WFUMB-EFSUMB guidelines have added the urinary bladder under non-hepatic applications of CEUS. The technique is able to distinguish between benign tissue, such as clots or hematoma, and malignant lesions by perfusing the mass with contrast agent. Thanks to the different perfusion rates of the various layers of the bladder wall, CEUS is also able to predict tumor invasion depth and stage. Despite that, current urological guidelines do not include CEUS as a plausible imaging technique for bladder urothelial carcinoma. The main reason for this omission might be the presence of scarce randomized evidence and the absence of large validated series. In this review, we describe the rationale behind the use of CEUS in bladder cancer and the added value of this imaging technique in the detection and staging of bladder lesions. In addition, we researched the available literature on the topic and then described the results of randomized clinical trials and a meta-analysis investigating the accuracy of CEUS in bladder cancer diagnosis and staging. The reported studies show that CEUS is a highly accurate diagnostic and staging tool for BC, reaching levels of specificity and sensitivity in differentiating between Ta-T1, or low-grade BC, and T2, or high-grade BC, that are comparable to those shown by the reference standard methods. Nonetheless, several limitations were found and are highlighted in this review. The aim of this study is to further validate and promote the use of CEUS as a quick, economic and effective diagnostic tool for this high-impact disease.